Retrospective Database Analysis of IMLYGIC™ for Treatment of Melanoma
Research type
Research Study
Full title
Clinical Characteristics of The First IMLYGIC™ Patients With Advanced Melanoma Treated in Routine Clinical Practice, in Selected European Countries.
IRAS ID
219157
Contact name
Mark Harries
Contact email
Sponsor organisation
Amgen
Clinicaltrials.gov Identifier
EMEA/H/C/002771, Product Reference
Duration of Study in the UK
0 years, 4 months, 7 days
Research summary
Patients diagnosed with unresectable melanoma stage IIIB, IIIC, or IVM1a, received at least one IMLYGIC™ dose as per the EU marketing authorisation during the study eligibility period, was 18 years of age or older at the time of first IMLYGIC™ administration, and patient/legal representative provided written informed consent will participate in this study.\n\nSites may be located in Austria, Finland, Germany, Sweden, the United Kingdom (UK), and potentially other European countries.\n\nParticipating investigators will complete a one time survey. Participant data collection will begin in February 2017 and end in Apr 2017. Final report of study results will be June/July2017.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
17/NW/0077
Date of REC Opinion
16 Jan 2017
REC opinion
Favourable Opinion